1. Health technology

  2. •

    Pharmaceuticals: major
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR

Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR

75.60
BRL
-3.20
(-4.06%)
4.40EPS
18.28P/E
1.53TMarket Cap
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR
B3:N1VS34
(B3)

Recent

price

75.60

P/E

ratio

18.28

div

yld

4.17%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
2.12
2.35
1.98
1.93
2.21
2.11
2.13
1.81
1.96
2.06
1.95
1.8
1.85
1.9
2.34
2.33
3.07
Revenue per Share
0.4
0.35
0.35
0.34
0.42
0.74
0.29
0.32
0.54
0.5
0.31
0.98
0.3
0.6
0.54
0.57
0.69
Basic EPS, GAAP
0.49
0.47
0.43
0.36
0.43
0.35
0.37
0.43
0.49
0.48
0.43
0.51
0.51
0.48
0.62
0.63
0.81
Free Cash Flow per Basic Share
0.18
0.21
0.23
0.22
0.28
0.28
0.28
0.27
0.3
0.28
0.27
0.3
0.32
0.3
0.34
0.32
0.49
Dividend per Share
2.59
2.58
2.62
2.75
2.94
3.27
3.22
3.13
3.36
2.38
2.23
2.77
2.6
1.93
2.03
1.92
1.77
Book Value per Share
-0.07
0.15
0.29
0.57
0.73
0.49
0.54
0.52
0.2
0.01
-0.4
0.16
-0.07
-0.15
-0.35
-0.37
-1.17
Tangible Book Value per Share
22,760
23,716
24,076
24,304
24,154
23,925
23,676
23,358
23,089
22,810
22,671
22,332
21,715
20,677
20,092
19,305
14,737
Basic Weighted Avg Shares
48,230
55,682
47,553
47,023
53,304
50,470
50,314
42,264
45,297
47,070
44,144
40,112
40,160
39,245
46,921
44,907
45,278
Sales/Revenue/Turnover
22.35
18.16
22.14
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.18
Operating Margin (%)
3,198
5,428
4,064
3,929
4,653
5,480
6,150
4,612
5,120
5,634
5,719
5,105
6,196
6,962
5,506
4,219
4,425
Depreciation Expense
9,161
8,384
8,482
8,184
10,147
17,812
6,831
7,501
12,392
11,345
7,141
21,911
6,427
12,490
10,833
11,081
10,190
Net Income, GAAP
14.81
14.05
15.18
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
17.9
Effective Tax Rate (%)
18.99
15.06
17.84
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
22.5
Profit Margin (%)
1,896
878
3,617
3,723
10,523
-864
2,770
4,679
5,852
1,199
-2,996
14,148
7,627
3,441
918
2,521
-3,552
Working Capital
13,432
12,993
12,610
10,028
13,714
16,354
18,215
22,614
22,079
21,328
24,752
22,369
20,128
16,850
20,805
23,448
31,628
LT Debt
65,262
61,839
63,376
66,429
70,408
77,249
76,221
72,277
77,323
53,717
50,131
61,865
54,910
39,321
40,030
36,884
33,885
Total Equity
10.92
9.95
10.63
10.01
10.82
7.99
7.08
6.83
7.03
7.18
8.59
9.56
7.01
10.49
17.26
17.4
16.4
Return on Invested Capital (%)
11.9
10.58
11.02
10.5
12.35
19.37
7.48
8.09
12.66
12.58
9.39
25.99
8.25
18.52
17.92
17.81
16.75
Return on Capital (%)
15.47
13.87
13.57
12.63
14.85
24.15
8.91
10.11
16.58
17.33
13.77
39.2
11.03
26.55
27.35
28.97
30.49
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,583
6,298
7,967
LT Borrowings
22,135
29,898
30,285
LT Finance Leases
1,313
1,328
1,343
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18,998
18,998
18,924
Market Capitalization
209,231
231,121
239,206

Working Capital

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
24,136
21,244
22,095
Cash, Cash Equivalents & STI
9,139
5,571
6,212
Accounts Receivable, Net
7,082
7,494
7,784
Inventories
4,967
5,019
5,025
Total Current Liabilities
21,615
25,050
25,647
Payables & Accruals
7,541
4,894
5,307
ST Debt
4,583
6,298
7,967
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.9%
-4.46%
-7.86%
Free Cash Flow
4.41%
5.24%
-3.55%
Net Income, GAAP
18.74%
43.91%
2.29%
Sales/Revenue/Turnover
-0.75%
0.8%
-4.29%
Total Cash Common Dividend
-0.39%
0.56%
-10.43%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,920
11,563
11,134
12,299
46,921
2025
12,038
11,759
11,420
10,982
44,907
2026
10,798
12,078
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.14
0.13
0.13
0.54
2025
0.16
0.17
1.62
0.1
0.57
2026
0.13
0.14
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.11
- -
- -
0.34
2025
0.24
0.1
- -
- -
0.32
2026
0.26
0.12
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business

Company News

Company News APIChatGPT

  • reuters.com

    Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

  • reuters.com

    Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows

  • zacks.com

    Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

  • seekingalpha.com

    Novartis: The Sell-Off Creates An Attractive Entry Point

  • reuters.com

    Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • zacks.com

    NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • reuters.com

    US FDA expands use of Novartis drug for chronic skin condition

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • zacks.com

    Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

  • cnbc.com

    Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

  • wsj.com

    Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal

  • reuters.com

    Novartis signs mRNA deal for about $7.8 billion with China's Abogen

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • gurufocus.com

    Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • defenseworld.net

    Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern

  • zacks.com

    Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs